On November 3, 2026, Algerian Minister of Pharmaceutical Industry, Dr. Wassim Qouideri, received Swiss Ambassador to Algeria, Marion Wechsler. During the meeting, Qouideri highlighted the importance of developing genetic treatments. This development is expected to enhance the services provided by the Algerian Institute for Cell Therapy. The institute is being developed by the public company "Saidal" in collaboration with foreign institutions.
The Algerian Institute for Cell Therapy is a national project aimed at providing advanced therapeutic technologies in Algeria. It seeks to improve patient care using the latest scientific and medical innovations. Qouideri emphasized that genetic treatments offer promising prospects for treating various incurable diseases. This development is expected to improve healthcare services and enhance Algeria's healthcare sovereignty.
The Minister expressed his sector's readiness to support economic operators interested in developing their activities and investing in Algeria. This support aims to foster industrial partnerships, transfer expertise, and modernize technologies. It also seeks to develop national capacities in the pharmaceutical industry. Qouideri's statement underscores the government's efforts to promote investment and growth in the sector.
Swiss Ambassador Marion Wechsler praised the strong bilateral relations between Algeria and Switzerland, particularly in the pharmaceutical industry. She expressed her country's interest in strengthening cooperation and expanding partnerships in innovative medicine and advanced therapeutic technologies. Wechsler's comments highlight the potential for increased collaboration between the two nations.
The meeting between Qouideri and Wechsler reflects the ongoing efforts to enhance cooperation between Algeria and Switzerland. The two countries have a history of collaboration in various fields, including healthcare and pharmaceuticals. This cooperation is expected to continue and expand in the future.
Algeria has been making significant strides in developing its pharmaceutical industry. The government has been working to improve the sector's infrastructure and capabilities. This includes investing in research and development, as well as collaborating with foreign institutions. These efforts aim to enhance the country's healthcare services and reduce its reliance on imported medicines.
The development of genetic treatments in Algeria has the potential to significantly impact the country's healthcare sector. It could provide new treatment options for patients with incurable diseases. Additionally, it could help to reduce healthcare costs and improve the overall quality of life for Algerian citizens. The Algerian government's commitment to investing in this area is a positive step towards achieving these goals.
Key points
- Algerian Minister of Pharmaceutical Industry emphasizes the significance of genetic treatments.
- The Algerian Institute for Cell Therapy is a national project aimed at providing advanced therapeutic technologies.
- Algeria and Switzerland are exploring opportunities to strengthen cooperation in the pharmaceutical industry.
